Equities Analysts Issue Forecasts for T2 Biosystems Inc.’s FY2019 Earnings (TTOO)
T2 Biosystems Inc. (NASDAQ:TTOO) – Equities research analysts at Leerink Swann issued their FY2019 earnings estimates for shares of T2 Biosystems in a report released on Wednesday. Leerink Swann analyst P. Souda forecasts that the firm will post earnings of ($0.78) per share for the year. Leerink Swann currently has a “Market Perform” rating and a $5.00 target price on the stock.
TTOO has been the subject of several other research reports. Zacks Investment Research raised shares of T2 Biosystems from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a research report on Saturday, November 5th. Canaccord Genuity reaffirmed a “buy” rating and set a $9.00 price target on shares of T2 Biosystems in a research report on Thursday, September 22nd. Cantor Fitzgerald reduced their price target on shares of T2 Biosystems from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, November 2nd. Finally, WBB Securities raised shares of T2 Biosystems from a “buy” rating to a “strong-buy” rating and upped their price target for the company from $11.00 to $12.00 in a research report on Wednesday, July 20th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. T2 Biosystems presently has an average rating of “Hold” and a consensus price target of $8.46.
T2 Biosystems (NASDAQ:TTOO) opened at 6.89 on Friday. The firm’s 50 day moving average is $6.75 and its 200 day moving average is $7.29. The stock’s market capitalization is $209.67 million. T2 Biosystems has a 1-year low of $4.92 and a 1-year high of $12.00.
T2 Biosystems (NASDAQ:TTOO) last posted its quarterly earnings results on Tuesday, November 1st. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.01. The firm had revenue of $1.08 million for the quarter, compared to the consensus estimate of $2.03 million. T2 Biosystems had a negative net margin of 1,250.59% and a negative return on equity of 134.73%. The business’s revenue was up 2.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.57) earnings per share.
A number of hedge funds and other institutional investors have recently bought and sold shares of TTOO. KCG Holdings Inc. acquired a new position in T2 Biosystems during the second quarter valued at $100,000. Teachers Advisors Inc. increased its position in T2 Biosystems by 20.8% in the second quarter. Teachers Advisors Inc. now owns 20,063 shares of the company’s stock valued at $158,000 after buying an additional 3,448 shares during the last quarter. California State Teachers Retirement System increased its position in T2 Biosystems by 1.0% in the third quarter. California State Teachers Retirement System now owns 30,940 shares of the company’s stock valued at $224,000 after buying an additional 300 shares during the last quarter. Bank of New York Mellon Corp increased its position in T2 Biosystems by 17.1% in the second quarter. Bank of New York Mellon Corp now owns 44,105 shares of the company’s stock valued at $348,000 after buying an additional 6,435 shares during the last quarter. Finally, BlackRock Investment Management LLC increased its position in T2 Biosystems by 62.8% in the second quarter. BlackRock Investment Management LLC now owns 54,728 shares of the company’s stock valued at $432,000 after buying an additional 21,119 shares during the last quarter. Institutional investors and hedge funds own 80.38% of the company’s stock.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Stock Ratings for T2 Biosystems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc. and related stocks with our FREE daily email newsletter.